Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments –– ADOA is a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback